Proteomic analysis of osteogenic sarcoma: Association of tumour necrosis factor with poor prognosis

International Journal of Experimental Pathology

Volumn 91, Issue 4, 2010, Pages 335-349

  Cates, Justin M M ^a   Friedman, David B ^b   Seeley, Erin H ^b   Dupont, William D ^a   Schwartz, Herbert S ^c   Holt, Ginger E ^c   Caprioli, Richard M ^b   Young, Pampee P ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

macrophage migration inhibitory factor; metastasis; osteosarcoma; prognosis; proteomics; tumour necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL RECORD REVIEW; METASTASIS; MOLECULE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SCHOOL CHILD; TUMOR CELL LINE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; KAPLAN-MEIERS ESTIMATE; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; OSTEOSARCOMA; PROPORTIONAL HAZARDS MODELS; PROTEOMICS; RISK ASSESSMENT; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955073572     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00711.x     Document Type: Article

References (49)

1. Allred D.C., Clark G.M., Elledge R. et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl Cancer Inst. 85, 200 206.
2. Anderson G.M., Nakada M.T., DeWitte M. (2004) Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4, 314 320.
3. Balkwill F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361 371.
4. Brown E.R., Charles K.A., Hoare S.A. et al. (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann. Oncol. 19, 1340 1346.
5. Caldwell R.L. Caprioli R.M. (2005) Tissue profiling by mass spectrometry: a review of methodology and applications. Mol. Cell Proteomics 4, 394 401.
6. Clark J.C., Dass C.R., Choong P.F. (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J. Cancer Res. Clin. Oncol. 134, 281 297.
7. Cvetkovic I. Stosic-Grujicic S. (2006) Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Int. Immunopharmacol. 6, 1527 1534.
8. Dabideen D.R., Cheng K.F., Aljabari B., Miller E.J., Pavlov V.A., Al-Abed Y. (2007) Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J. Med. Chem. 50, 1993 1997.
9. Decker E.D., Zhang Y., Cocklin R.R., Witzmann F.A., Wang M. (2003) Proteomic analysis of differential protein expression induced by ultraviolet light radiation in HeLa cells. Proteomics 3, 2019 2027.
10. Denz A., Pilarsky C., Muth D., Ruckert F., Saeger H.D., Grutzmann R. (2009) Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J. Surg. Res. May 3. [Epub ahead of print] doi: http://dx.doi.org/10.1016/j.jss.2009.03.048.
11. Diresta G.R., Nathan S.S., Manoso M.W. et al. (2005) Cell proliferation of cultured human cancer cells are affected by the elevated tumor pressures that exist in vivo. Ann. Biomed. Eng. 33, 1270 1280.
12. Friedman D.B., Hill S., Keller J.W. et al. (2004) Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4, 793 811.
13. Friedman D.B., Wang S.E., Whitwell C.W., Caprioli R.M., Arteaga C.L. (2007) Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. Mol. Cell Proteomics 6, 150 169.
14. Garai J. Lorand T. (2009) Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. Curr. Med. Chem. 16, 1091 1114.
15. Gorlick R., Anderson P., Andrulis I. et al. (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin. Cancer Res. 9, 5442 5453.
16. Han I., Lee M.R., Nam K.W., Oh J.H., Moon K.C., Kim H.S. (2008) Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Clin. Orthop. Relat. Res. 466, 2107 2113.
17. Harrell Jr. F.E. (2009) Hmisc: Harrell miscellaneous. R package version 3.6-0. http://CRAN.R-project.org/package=Hmisc.
18. Havell E.A., Fiers W., North R.J. (1988) The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med. 167, 1067 1085.
19. Hayden J.B. Hoang B.H. (2006) Osteosarcoma: basic science and clinical implications. Orthop. Clin. North Am. 37, 1 7.
20. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L. (2000) An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 18, 261 271.
21. Khanna C., Wan X., Bose S. et al. (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat. Med. 10, 182 186.
22. Kulbe H., Thompson R., Wilson J.L. et al. (2007) The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585 592.
23. Leonard P., Sharp T., Henderson S. et al. (2003) Gene expression array profile of human osteosarcoma. Br. J. Cancer 89, 2284 2288.
24. Li B., Vincent A., Cates J., Brantley-Sieders D.M., Polk D.B., Young P.P. (2009) Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 69, 338 348.
25. Madhusudan S., Foster M., Muthuramalingam S.R. et al. (2004) A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10, 6528 6534.
26. Madhusudan S., Muthuramalingam S.R., Braybrooke J.P. et al. (2005) Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950 5959.
27. Marina N., Gebhardt M., Teot L., Gorlick R. (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9, 422 441.
28. Meier B.W., Gomez J.D., Zhou A., Thompson J.A. (2005) Immunochemical and proteomic analysis of covalent adducts formed by quinone methide tumor promoters in mouse lung epithelial cell lines. Chem. Res. Toxicol. 18, 1575 1585.
29. Meyer-Siegler K.L., Iczkowski K.A., Leng L., Bucala R., Vera P.L. (2006) Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol. 177, 8730 8739.
30. Mitchell R.A. (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell. Signal. 16, 13 19.
31. Mocellin S. Nitti D. (2008) TNF and cancer: the two sides of the coin. Front. Biosci. 13, 2774 2783.
32. Morand E.F. (2005) New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern. Med. J. 35, 419 426.
33. Nakano T., Tani M., Ishibashi Y. et al. (2003) Biological properties and gene expression associated with metastatic potential of human osteosarcoma. Clin. Exp. Metastasis 20, 665 674.
34. Nathan S.S., Huvos A.G., Casas-Ganem J.E. et al. (2008) Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J. Orthop. Res. 26, 1520 1525.
35. Nishihira J., Ishibashi T., Fukushima T., Sun B., Sato Y., Todo S. (2003) Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann. N Y Acad. Sci. 1995, 171 182.
36. Oda S., Oda T., Nishi K. et al. (2008) Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS ONE 3, e2215.
37. Ogawa H., Nishihira J., Sato Y. et al. (2000) An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 12, 309 314.
38. R Development Core Team (2009) R: A language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org.
39. Ren Y., Chan H.M., Fan J. et al. (2006) Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene 25, 3501 3508.
40. Reyzer M.L., Caldwell R.L., Dugger T.C. et al. (2004) Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 64, 9093 9100.
41. Schmidt J., Strauss G.P., Schon A. et al. (1988) Establishment and characterization of osteogenic cell lines from a spontaneous murine osteosarcoma. Differentiation 39, 151 160.
42. Sethi G., Sung B., Aggarwal B.B. (2008) TNF: a master switch for inflammation to cancer. Front. Biosci. 13, 5094 5107.
43. Sun B., Nishihira J., Yoshiki T. et al. (2005) Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the rho-dependent pathway. Clin. Cancer Res. 11, 1050 1058.
44. Szlosarek P.W. Balkwill F.R. (2003) Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4, 565 573.
45. Szlosarek P., Charles K.A., Balkwill F.R. (2006) Tumour necrosis factor-alpha as a tumour promoter. Eur. J. Cancer 42, 745 750.
46. Therneau T. Lumley T. (2009) survival: Survival analysis, including penalised likelihood. R package version 2.35-4. http://CRAN.R-project.org/ package=survival.
47. UniProt Consortium. (2009) The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res. 37, D169 D174.
48. Wang L.L. (2005) Biology of osteogenic sarcoma. Cancer J. 11, 294 305.
49. Xu B.J., Shyr Y., Liang X. et al. (2005) Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J. Am. Soc. Nephrol. 16, 2967 2975.